The FDA is re-evaluating the appropriateness of using noninferiority trial designs for anti-infectives used to treat community-acquired pneumonia (CAP), which could affect firms like Woodridge, Ill.-based Advanced Life Sciences Holdings Inc., whose new drug applications are in the works. (BioWorld Today) Read More
